Get the Stockscreener App
0.8807
1.70%
0.0147
After Hours:
.87
-0.0107
-1.21%
Atyr Pharma Inc stock is traded at $0.8807, with a volume of 3.82M.
It is up +1.70% in the last 24 hours and up +13.61% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$0.866
Open:
$0.8757
24h Volume:
3.82M
Relative Volume:
0.36
Market Cap:
$86.30M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.50%
1M Performance:
+13.61%
6M Performance:
-75.54%
1Y Performance:
-71.03%
1-Day Range:
$0.8226
$0.8815
1-Week Range:
$0.8226
$1.02
52-Week Range:
$0.6816
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.8807 | 84.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Investor Alert: Deadline Approaching to Join aTyr Pharma, Inc. (ATYR) Class ActionContact Levi & Korsinsky - The Globe and Mail
ATYR Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ATYR To Contact Him Directly To Discuss Their Options - MarketScreener
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATYR - MarketScreener
Does aTyr Pharma Inc. fit your quant trading modelJuly 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Ranking aTyr Pharma Inc. among high performing stocks via tools2025 Trading Recap & Low Risk High Win Rate Picks - newser.com
What earnings revisions data tells us about aTyr Pharma Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
aTyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - Lelezard
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR)Join by December 8, 2025Contact Levi & Korsinsky - Stockhouse
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages aTyr Pharma, - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
Is aTyr Pharma Inc. stock cheap at current valuation2025 Winners & Losers & Precise Trade Entry Recommendations - newser.com
What catalysts could drive aTyr Pharma Inc. stock higherMarket Sentiment Summary & Reliable Entry Point Alerts - newser.com
Real time breakdown of aTyr Pharma Inc. stock performance2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Is aTyr Pharma Inc. stock poised for growthGDP Growth & Weekly Market Pulse Alerts - newser.com
aTyr Pharma Inc. stock prediction for this weekGDP Growth & Verified High Yield Trade Plans - newser.com
Lost Money on aTyr Pharma, Inc. (ATYR)? Contact Levi & Korsinsky to Join Class Action Before December 8, 2025 - ACCESS Newswire
December 8, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATYR - Bluefield Daily Telegraph
Levi & Korsinsky Notifies aTyr Pharma, Inc. (ATYR) InvestorsLead Plaintiff Deadline on December 8, 2025 - Stockhouse
ATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) - GlobeNewswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
aTyr Pharma (ATYR) to Release Earnings on Thursday - MarketBeat
Relative strength of aTyr Pharma Inc. in sector analysisWeekly Trend Recap & Reliable Intraday Trade Plans - newser.com
Will aTyr Pharma Inc. (471A) stock outperform benchmarksInsider Selling & Weekly Chart Analysis and Guides - newser.com
How aTyr Pharma Inc. (471A) stock reacts to stronger dollarPortfolio Gains Summary & Daily Growth Stock Investment Tips - newser.com
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, - GlobeNewswire
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming ... - Caledonian Record
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ATYR - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming DeadlinesATYR - FinancialContent
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors - GlobeNewswire
ATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged — Hagens Berman - Morningstar
Why aTyr Pharma Inc. stock could see breakout soonWeekly Investment Report & Entry Point Confirmation Signals - newser.com
Is aTyr Pharma Inc. stock a defensive play in 2025Weekly Trend Summary & Comprehensive Market Scan Insights - newser.com
Burned by aTyr Pharma, Inc.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Does aTyr Pharma Inc. show high probability of reboundPortfolio Gains Summary & Advanced Technical Analysis Signals - newser.com
Lawsuit filed for Investors who lost money with shares of aTyr Pharma, Inc. (NASDAQ: ATYR) - openPR.com
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportu - GuruFocus
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about ... - Bluefield Daily Telegraph
Investors who lost money on aTyr Pharma, Inc.(ATYR) should - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Statistical indicators supporting aTyr Pharma Inc.’s strengthProfit Target & Fast Moving Trade Plans - newser.com
Will aTyr Pharma Inc. stock go up soonRate Cut & Verified Momentum Watchlists - newser.com
How aTyr Pharma Inc. stock responds to policy changesJuly 2025 Closing Moves & Weekly Market Pulse Updates - fcp.pa.gov.br
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr ... - Black Hills Pioneer
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Atyr Pharma Inc Stock (ATYR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):